What is the standard dosing protocol for Cagrilintide?

Conventional Cagrilintide dosing is 1.2-2.4 mg 1x weekly subq via subq. For anabolic and recovery use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

How does Cagrilintide's half-life affect dosing?

Cagrilintide has a plasma half-life of ~7 days, which is long enough that single-weekly dosing is operationally viable. The receptor occupancy curve under 1x weekly subq dosing at 1.2-2.4 mg per dose explains the typical onset timeline for anabolic and recovery endpoints.

What is the regulatory status of Cagrilintide?

Cagrilintide regulatory status: Investigational (Phase III combined with semaglutide as CagriSema) in the United States; WADA status not on prohibited list; research level phase iii trials underway. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For anabolic and recovery use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What should I look for in Cagrilintide sourcing and quality?

Acceptable Cagrilintide certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching ~4400 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Home/ Compounds/ Cagrilintide

Cagrilintide

Body Composition

For the body-composition and physique community, Cagrilintide is run inside a training-driven framework where the compound supports rather than substitutes for stimulus and nutrition. Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex) Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing.. The ~7 days pharmacokinetic profile determines training-day versus rest-day dosing, while the subq administration shapes injection-site rotation and protocol planning.

Body Composition / Training Applications

Lean MassCardiovascular ConditioningWorkout RecoveryFat LossRecovery

Key Takeaways

Body composition lens: response to Cagrilintide is proportional to training stimulus and nutritional adequacy.
Mechanism: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex).
Body composition dose: 1.2-2.4 mg 1x weekly subq via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing. The body composition layer follows: how the compound contributes to anabolic substrate, how it shapes the recovery window between training sessions, how training-day dosing differs from rest-day dosing, and which structural-adaptation dimension (hyperplasia or hypertrophy) is most affected by Cagrilintide.

Recovery window and training frequency

The most reliably reported effect of Cagrilintide in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Anabolic substrate and protein synthesis

Cagrilintide's relevance to body composition depends on where in the anabolic cascade it acts. It acts on adjacent rather than directly anabolic pathways, but the contribution to recovery, connective tissue, and inflammatory tone produces measurable body-composition effects in trained users. The downstream effect on body composition is dose- and training-dependent.

Hyperplasia and structural adaptation

Where Cagrilintide demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Body Composition / Training Applications

Body Recomposition

For body recomposition, Cagrilintide integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Fat Loss

Fat Loss responds to Cagrilintide with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Strength

The body composition community converges on Cagrilintide for strength with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Endurance

For endurance, Cagrilintide integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1.2-2.4 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.2-2.4 mg	4–6 weeks initial cycle
Body Composition focus	SubQ	1.2-2.4 mg	1x weekly SubQ
Maintenance phase	SubQ	1.2-2.4 mg	Ongoing with periodic pauses

Dose timing for Cagrilintide is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Cagrilintide stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

Cagrilintide + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with Cagrilintide's mechanism in body composition / training protocols.
Cagrilintide + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with Cagrilintide's mechanism in body composition / training protocols.
Cagrilintide + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Cagrilintide's mechanism in body composition / training protocols.
Cagrilintide + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Cagrilintide's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Investigational (Phase III combined with semaglutide as CagriSema) Research: Phase III trials underway

Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy.

Lens-specific safety considerations for body composition / training use of Cagrilintide: Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Once-weekly cagrilintide for weight management in people with overweight and obesity

PMID 34861246

Supporting

CagriSema (cagrilintide + semaglutide) in type 2 diabetes

PMID 37271482

Cagrilintide vs Related Peptides

Compound	Profile	Onset	Best For
Cagrilintide	Long-acting amylin analogue	~7 days	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Training-day only or daily dosing?

For most peptide compounds with short-to-moderate half-life, training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The choice depends on the user's training volume and the compound's pharmacokinetics. Daily dosing for 4-7 days is the default; training-day-only protocols are appropriate for lower-volume programmes.

Should I cycle Cagrilintide?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

How does Cagrilintide compare to AAS for body composition?

Peptide therapeutics including Cagrilintide produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Effect timeline for body composition?

Acute pump and recovery effects within 1–2 weeks. Visible body composition shifts at 4–8 weeks for trained users with adequate nutrition. Peak effect at the end of a 12-week cycle; partial regression during the 4-week off-period. Total trajectory is incremental rather than dramatic.

What is Cagrilintide?

Cagrilintide (also known as AM833) is a 37-residue long-acting amylin analogue with a molecular weight of ~4400 Da and a plasma half-life of ~7 days. Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing. The compound is studied primarily in the body composition / training domain for the applications outlined above.

What is the evidence base for Cagrilintide?

Cagrilintide's evidence base sits at phase iii trials underway. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The body composition / training interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Clinical Protocol

Start a Cagrilintide Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified Cagrilintide and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: ~4400 Da
Sequence length: 37 aa
Half-life: ~7 days
WADA: Not on prohibited list
FDA: Investigational (Phase III combined with semaglutide as CagriSema)
Research: Phase III trials underway

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Cagrilintide unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for Cagrilintide

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised